Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer

APPROVED_FOR_MARKETING

Conditions studied: Prostate Cancer, Prostate, Prostate Adenocarcinoma

In brief

This expanded access protocol provides eligible participants with investigational 68Ga-PSMA-11 PET imaging to detect and localize prostate cancer for initial and subsequent treatment strategy.

Key facts

Study ID

NCT04377152

Run by

University of California, San Francisco

Last updated by the study team

2021-03-01

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Histopathologically confirmed or biopsy proven prostate adenocarcinoma.
• Concern for metastatic disease in one of the following settings:
• Initial staging with intermediate to high risk prostate cancer.
• Biochemical recurrence after initial therapy.
• Ability to understand a written informed consent document, and the willingness to sign it

You may not qualify if…

• Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation

Where it is running

• University of California, San Francisco — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.